Software validation report shows single biomarkers often outperform panels for breast cancer diagnosis.
This software validation report assesses the TholdStormDX v0.0.1 tool using datasets from four diagnostic domains: Pulmonary Nodules, Hepatocellular Carcinoma, Cervical Cancer, and Breast Cancer. The study aimed to derive cut-off points for individual biomarkers and multivariable combinations to assess model performance and generalizability. No absolute numbers or p-values were reported in the validation workflow.
In the analysis of Breast Cancer diagnosis, the individual predictor outperformed the optimized panel, demonstrating a sensitivity of 0.953 and a specificity of 0.952 in the Test set. Conversely, for Hepatocellular Carcinoma, the multivariable combination showed superior performance with a sensitivity of 0.707 and a specificity of 0.718 in the Test set. The report also identified scenarios where single biomarkers outperformed complex panels and flagged metric degradation when noisy variables were included.
The authors note that limitations regarding the study design and generalizability were not reported. Funding sources and conflicts of interest were not disclosed. The practice relevance focuses on mitigating local minima and promoting clinical parsimony, enabling researchers to objectively identify when a single biomarker is sufficient and when a panel provides real added value. Clinicians should not infer clinical efficacy of the tool in real-world settings beyond the described validation workflow, nor assume the tool is approved for clinical use.